Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer.

N A Spry¹, L Kristjanson, B Hooton, L Hayden, G Neerhut, H Gurney, T Corica, E Korbel, S Weinstein, K McCaul

¹Department of Medicine, University of Western Australia, Perth, WA, Australia. Nigel.Spry@health.wa.gov.au

Abstract

Health-related quality of life (HQOL) research is a means of broadening the assessment of treatment effects. This longitudinal study investigated the dynamic change to quality of life (QOL) and testosterone dependant physiology in men commencing an intermittent maximal androgen blockade program (IMAB). Two hundred and fifty men were accrued to the multi-centre study of IMAB (Flutamide 250 mg TDS,…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.